ArticleScience (New York, N.Y.)2021
The gRAMP CRISPR-Cas effector is an RNA endonuclease complexed with a caspase-like peptidase.
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Craspase Protease Activation Is Sensitive to Oncogenic Single-Nucleotide RNA Mismatches.ACS chemical biology · 2026Article
- Structural mechanism of SAM-AMP and SAM-AMPNature communications · 2026Article
- A synthetic system for RNA-responsive pyroptosis based on type III-E CRISPR nuclease-protease.Nature communications · 2026Article
- Synthetic Type III-E CRISPR-Cas Effectors for Programmable RNA-targeting.Journal of molecular biology · 2026Article
- CRISPR-Cas13b mediated gene knockdowns in Leishmania infantum.International journal for parasitology. Drugs and drug resistance · 2025Article
- A NanoLock-enabled, Craspase-based strategy for highly sensitive RNA detection.Nucleic acids research · 2025Article
- TIGR-Tas: A family of modular RNA-guided DNA-targeting systems in prokaryotes and their viruses.Science (New York, N.Y.) · 2025Article
- CRISPR RNA binding drives structural ordering that primes Cas7-11 for target cleavage.Nucleic acids research · 2025Article
- Review
- CRISPR technology in human diseases.MedComm · 2024Review
- Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.Nature chemical biology · 2024Review
- Craspase Orthologs Cleave a Nonconserved Site in Target Protein Csx30.ACS chemical biology · 2024Article
- Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in human cells.Science (New York, N.Y.) · 2024Article
- Structural basis of negative regulation of CRISPR-Cas7-11 by TPR-CHAT.Signal transduction and targeted therapy · 2024Article
- RNA targeting and cleavage by the type III-Dv CRISPR effector complex.Nature communications · 2024Article
- Type III-B CRISPR-Cas cascade of proteolytic cleavages.Science (New York, N.Y.) · 2024Article
- Programmable RNA writing with trans-splicing.bioRxiv : the preprint server for biology · 2024Article
- In Silico Design, In Vitro Construction, and In Vivo Application of Synthetic Small Regulatory RNAs in Bacteria.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Harnessing CRISPR-Cas adaptation for RNA recording and beyond.BMB reports · 2024Review
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type III CRISPR-Cas immunity is widespread in prokaryotes and is generally mediated by multisubunit effector complexes. These complexes recognize complementary viral transcripts and can activate ancillary immune proteins. Here, we describe a type III-E effector from
Indexed as
Identifiers
34446442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.